Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 142,803,904
  • Shares Outstanding, K 585,694
  • Annual Sales, $ 23,362 M
  • Annual Income, $ 7,842 M
  • 60-Month Beta 0.85
  • Price/Sales 6.02
  • Price/Cash Flow 12.71
  • Price/Book 13.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 3.75
  • Number of Estimates 11
  • High Estimate 4.05
  • Low Estimate 3.46
  • Prior Year 3.66
  • Growth Rate Est. (year over year) +2.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
237.78 +2.54%
on 09/24/20
260.06 -6.25%
on 09/03/20
-4.40 (-1.77%)
since 08/25/20
3-Month
229.98 +6.02%
on 06/29/20
264.97 -7.98%
on 07/06/20
+8.71 (+3.70%)
since 06/25/20
52-Week
177.05 +37.71%
on 03/23/20
264.97 -7.98%
on 07/06/20
+47.76 (+24.36%)
since 09/25/19

Most Recent Stories

More News
Insights on the Neutropenia Treatment Global Market to 2026 - Featuring Amgen, Novartis & Pfizer Among Others - ResearchAndMarkets.com

The "Global Neutropenia Treatment Market By Distribution channel, By Treatment, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

AMGN : 243.82 (+1.46%)
NVS : 87.11 (+0.94%)
Simple Secrets Anyone Can Use to Reach Early Retirement - September 25, 2020

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments,...

CTRE : 17.27 (+1.56%)
BMY : 59.49 (+2.13%)
AMGN : 243.82 (+1.46%)
4 Biotech Stocks to Own for the Rest of 2020

The healthcare sector has been led by the biotech and pharmaceutical industries. These industries have led the fight against COVID and cancer. Here are four biotech stocks that should continue to benefit...

AMGN : 243.82 (+1.46%)
ALXN : 114.43 (+2.15%)
IMMU : 85.36 (+0.07%)
Is Moderna a Good Coronavirus Stock to Buy?

Moderna (MRNA) is one of the leading biotech manufacturers in the race to develop a coronavirus vaccine. The stock seems overvalued by traditional measures, but the company’s unique approach to developing...

MRNA : 69.47 (+6.60%)
AMGN : 243.82 (+1.46%)
GMAB : 36.02 (+2.94%)
ALXN : 114.43 (+2.15%)
[2020-2026] Wearable Injectors Market Size, Share, Growth, Revenue, Forecast, Driving Factors, Analysis Report

The global wearable injectors market is likely to derive growth from the increasing prevalence of chronic diseases. According to a report by Fortune Business Insights, titled "Wearable Injectors Market...

AMGN : 243.82 (+1.46%)
MDT : 103.16 (+1.87%)
UTHR : 100.45 (+0.55%)
Global Pharma and Biotech Preclinical Stage Partnering Report 2020: Access 1,800+ Partnering Deals Announced Since 2014

, /PRNewswire/ -- The report has been added to offering.

AMGN : 243.82 (+1.46%)
BIIB : 273.28 (+1.20%)
CELGZ : 0.47 (+2.15%)
MRK : 82.93 (-0.26%)
NVS : 87.11 (+0.94%)
Nutcracker Therapeutics Strengthens Leadership Team with Appointment of Madhavan Balachandran as Chief Operating Officer

, /PRNewswire/ -- Nutcracker Therapeutics, Inc., a company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, today announced the appointment of Madhavan...

AMGN : 243.82 (+1.46%)
Beyond Celiac Partners with Provention Bio on Phase 2 Clinical Trial for Promising Celiac Disease Therapeutic

Beyond Celiac, the leading catalyst for a celiac disease cure in the United States, today announced it has partnered with Provention Bio, Inc. (Nasdaq: PRVB) to provide clinical trial recruitment for the...

AMGN : 243.82 (+1.46%)
PRVB : 12.19 (+2.96%)
How Trading Your Own Retirement Can Fleece Your Financial Future - September 22, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

ABBV : 86.23 (+0.37%)
BMY : 59.49 (+2.13%)
AMGN : 243.82 (+1.46%)
Clinical Data From Full Phase 1 Cohort of Investigational Sotorasib Published in New England Journal of Medicine

Clinical Data From Full Phase 1 Cohort of Investigational Sotorasib Published in New England Journal of Medicine

AMGN : 243.82 (+1.46%)
BGNE : 282.40 (+2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 248.31
1st Resistance Point 246.06
Last Price 243.82
1st Support Level 239.69
2nd Support Level 235.57

See More

52-Week High 264.97
Last Price 243.82
Fibonacci 61.8% 231.38
Fibonacci 50% 221.01
Fibonacci 38.2% 210.64
52-Week Low 177.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar